James P. Luyendyk, Glenn H. Cantor, Daniel Kirchhofer, Nigel Mackman, Bryan L. Copple, and Ruipeng Wang Department of Pharmacology, Toxicology and Therapeutics, The University of Kansas Medical Center, Kansas City, Kansas; Discovery Toxicology, Bristol-Myers Squibb, Princeton, New Jersey; Department of Protein Engineering, Genentech, South San Francisco, California; and Division of Hematology/O...

Conference on Clinical Cancer Research November 2012 Re-evaluating Criteria for Accelerated Approval Richard L. Schilsky, Chief, Section of Hematology-Oncology, University of Chicago Medical Center David P. Schenkein, CEO, Agios Pharmaceuticals Wyndham H. Wilson, Senior Investigator, Chief, Lymphoma Therapeutics Section, NCI Cheryl L. Jernigan, Research/Patient Advocate, Susan G. Komen fo...

Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Division of Epidemiology, Department of Health Sciences Research, Division of Biostatistics, Department of Health Sciences Research, Division of Medical Oncology, Department of Oncology, and Molecular Genetics Research Laboratory, Mayo Clinic College of Medicine, Rochester, Minnesota and H. Le...

While biotechnology-derived allergen therapeutics show promise in improving the safety of immunotherapy, they may prove to have additional benefits in comparison to conventional allergenic extracts that deserve commentary. These issues range from product stability and compatibility to medical practice issues, which will be the focus of this article.

results like other cancers, prostate cancer is caused by an accumulation of genetic alterations in a cell that drives it to malignant growth. specific genes and gene alterations have been suggested to play a role in its development and progression. aneuploidy, loss of heterozygosity, gene mutations, hypermethylation and inactivation of specific tumour suppressor genes such as gstpi, apc, mdr1, ...

conclusions treatment with peg ifn α achieved a sustained negativity of hdv rna in about one third of patients. duration of peg ifn α therapy might be prolonged to at least 24 months or more to prevent the occurrence of hepatitis b virus (hbv) relapse encountered six months after completion of the treatment. patients and methods the sample size was based on available patients potentially to be ...